IBM Gives Long-Term Sales Growth Outlook That Tops Expectations
International Business Machines Corp. gave a stronger-than-expected revenue growth outlook for the coming years led by the expansion in its software business.
Novo Nordisk Expects Slowing Sales Growth This Year
The Danish pharmaceutical company expects sales growth to slow this year as capacity constraints, intensifying competition and pricing pressure drag on sales of its blockbuster weight-loss and diabetes drugs.
Novo Nordisk Annual Sales Jump on Higher Demand for Obesity Drugs
The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower growth this year.
As growth slows, CFO says Novo Nordisk is prepping for the next generation of weight loss drugs
Novo’s newest GLP-1, CagriSema, is the first big test of Novo Nordisk’s future as the leader in the obesity treatment market. The drug is more potent than Ozempic and Wegovy, expanding treatment to heavier patients while perhaps reducing treatment times for other individuals.
Wegovy sales double but Novo Nordisk sees slower sales growth in 2025
Wegovy maker Novo Nordisk on Wednesday forecast sales would grow at a slower rate this year although the outlook was roughly in line with market expectations as the pace of ferocious demand for its wildly popular obesity drug Wegovy eases somewhat.
Novo Nordisk sales beat estimates, but the story wasn’t Ozempic
Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t its wildly popular weight-loss drugs.
Novo Nordisk’s Wegovy Drug Sales Miss Expectations
The Danish pharmaceutical company’s blockbuster Wegovy weight-loss drug just missed sales expectations in the fourth quarter despite more than doubling on the year.
Novo Nordisk Q4 profit beats expectations, sees slower growth in 2025
By Maggie Fick and Stine Jacobsen LONDON/COPENHAGEN (Reuters) -Wegovy maker Novo Nordisk on Wednesday forecast slower sales growth for 2025 than 2024, a blow that is likely to deepen investor concerns that the company is losing its edge in the competitive obesity market to rival Eli Lilly.
Novo Nordisk's posts net profit beat as Wegovy sales jump 107% in fourth quarter
Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid soaring demand for its Wegovy obesity drugs. Net profit for the fourth quarter came in at 28.
AstraZeneca Expects Revenue, Earnings Growth Despite Sales Drop in China
Strength in the pharmaceutical major’s oncology business offset weak China sales, but the company has warned of a potential ...
Yum Brands Projects Stronger Sales Growth This Year
Fast-food restaurant owner Yum Brands is expecting stronger sales growth this year after it moves past challenges in its Middle East markets.
Wegovy sales double to boost Novo Nordisk's fourth quarter as growth set to slow
Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the final quarter of ...
Massive Job Cuts At Estée Lauder, Up To 11% Or 7,000 Employees, After Quarterly Sales Decline 6%
Estee Lauder will lay off between 5,800 and 7,000 employees after second-quarter sales plummeted 6% and operating income ...
Gilead: Strong Sales Growth Remains With Veklury And Beyond
Gilead Sciences, Inc.'s strong sales growth in Veklury, Livdelzi, and Trodelvy shows promise for long-term financial success.
Chipotle assesses fallout from Mexico tariffs, forecasts tepid annual sales growth
Chipotle Mexican Grill said on Tuesday that if President Donald Trump's proposed tariffs on Mexico go into full effect, the ...
Pandora Sales Sparkle But World’s Biggest Jeweler Cautions Over 2025
Pandora reported sales ahead of forecast thanks largely to its performance in the U.S., but economic and cost tailwinds look ...